US20030176357A1
(en)
*
|
1998-10-06 |
2003-09-18 |
Pospisilik Andrew J. |
Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
|
TWI249401B
(en)
*
|
1999-04-14 |
2006-02-21 |
Takeda Chemical Industries Ltd |
Agent for improving ketosis
|
PE20020323A1
(es)
*
|
2000-08-22 |
2002-06-13 |
Novartis Ag |
COMPOSICION FARMACEUTICA QUE COMPRENDE UN POTENCIADOR DE LA SECRESION DE INSULINA E INHIBIDORES DE HMG-Co-A-REDUCTASA O INHIBIDORES DE LA ENZIMA CONVERTIDORA DE ANGIOTENSINA (ACE)
|
US7144862B2
(en)
*
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
US7166578B2
(en)
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
US7199102B2
(en)
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
US7723303B2
(en)
*
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
US7148197B2
(en)
*
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
PT1345895E
(pt)
*
|
2000-12-21 |
2007-02-28 |
Sanofi Aventis Deutschland |
Novas difenilazetidinonas, processo para a sua preparação, fármacos contendo estes compostos e sua utilização para o tratamento de distúrbios do metabolismo lipídico
|
US7025985B2
(en)
*
|
2001-05-28 |
2006-04-11 |
Kanebo, Ltd. |
Dihydroxyphenyl compounds and glucoside compounds thereof
|
DE60218165T2
(de)
*
|
2001-05-28 |
2007-11-22 |
Kao Corp. |
Lipolyseförderer zur Reduzierung des Körpergewichts und medizinische Anwendung
|
US6987123B2
(en)
*
|
2001-07-26 |
2006-01-17 |
Cadila Healthcare Limited |
Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
|
AU2002336532C1
(en)
|
2001-09-14 |
2008-10-16 |
Amgen, Inc |
Linked biaryl compounds
|
US20030220374A1
(en)
*
|
2002-01-14 |
2003-11-27 |
Pharmacia Corporation |
Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
|
PE20040291A1
(es)
*
|
2002-03-22 |
2004-07-02 |
Novartis Ag |
COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA
|
US6716842B2
(en)
|
2002-04-05 |
2004-04-06 |
Warner-Lambert Company, Llc |
Antidiabetic agents
|
AU2003225027A1
(en)
*
|
2002-04-16 |
2003-11-03 |
Merck And Co., Inc. |
Combination therapy using a ppar alpha/gamma agonist
|
ITMI20021012A1
(it)
*
|
2002-05-13 |
2003-11-13 |
Giovanni Scaramuzzino |
Combinazione di un inibitore dell'enzima hmg-coa reduttasi e di un estere nitrato
|
EP1388352A1
(de)
*
|
2002-08-08 |
2004-02-11 |
Laboratoires Fournier S.A. |
Verwendung eines ppar-alpha-Agonisten zur Behandlung von Patienten, die an mit ppar-gamma-Agonisten-Behandlung assozierter Fettleibigkeit leiden
|
EP1546142A4
(de)
*
|
2002-08-29 |
2007-10-17 |
Merck & Co Inc |
Indole mit antidiabetischer wirkung
|
WO2004020408A1
(en)
|
2002-08-29 |
2004-03-11 |
Merck & Co., Inc. |
Indoles having anti-diabetic activity
|
JP4286782B2
(ja)
|
2002-09-12 |
2009-07-01 |
エフ.ホフマン−ラ ロシュ アーゲー |
糖尿病の治療に有用な、pparアゴニストとしてのn−置換−1h−インドール−5−プロピオン酸化合物
|
DE10300099A1
(de)
*
|
2003-01-07 |
2004-07-15 |
Bayer Healthcare Ag |
Indol-Phenylsulfonamid-Derivate
|
ATE374766T1
(de)
|
2003-01-14 |
2007-10-15 |
Arena Pharm Inc |
1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
|
EP1590336B1
(de)
|
2003-01-27 |
2010-12-01 |
Merck Sharp & Dohme Corp. |
Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
|
CN1794989A
(zh)
*
|
2003-04-14 |
2006-06-28 |
药物研发有限责任公司 |
用于治疗糖尿病的n-(((((1,3-噻唑-2-基)氨基)羰基)苯基)磺酰基)苯丙氨酸衍生物及相关化合物
|
US7981915B2
(en)
*
|
2003-04-30 |
2011-07-19 |
Beth Israel Deaconess Medical Center |
Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
|
WO2004098510A2
(en)
*
|
2003-04-30 |
2004-11-18 |
Beth Israel Deaconess Medical Center |
Cystic fibrosis therapy
|
EP1620420A2
(de)
|
2003-04-30 |
2006-02-01 |
The Institutes for Pharmaceutical Discovery, LLC |
Substituierte carbonsäuren
|
WO2004100895A2
(en)
*
|
2003-05-13 |
2004-11-25 |
Pharmacia Corporation |
Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
|
WO2004108126A1
(en)
*
|
2003-06-06 |
2004-12-16 |
Snowden Pharmaceuticals, Llc |
Fibric acid derivatives for the treatment of irritable bowel syndrome
|
EP1635773A2
(de)
*
|
2003-06-06 |
2006-03-22 |
Merck & Co., Inc. (a New Jersey corp.) |
Kombinationstherapie zur behandlung von hypertonie
|
MXPA06000554A
(es)
|
2003-07-14 |
2006-07-03 |
Arena Pharm Inc |
Derivados arilo y heteroarilo fusionados como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con los mismos.
|
DE10335449A1
(de)
*
|
2003-08-02 |
2005-02-17 |
Bayer Healthcare Ag |
Bicyclische Indolinsulfonamid-Derivate
|
DE10337839A1
(de)
*
|
2003-08-18 |
2005-03-17 |
Bayer Healthcare Ag |
Indolin-Derivate
|
US20050074443A1
(en)
*
|
2003-10-03 |
2005-04-07 |
Treadwell Benjamin V. |
Methods of attenuating autoimmune disease and compositions useful therefor
|
AU2004291259A1
(en)
*
|
2003-11-05 |
2005-06-02 |
F. Hoffmann-La Roche Ag |
Heteroaryl derivatives as PPAR activators
|
RU2367654C2
(ru)
|
2003-11-05 |
2009-09-20 |
Ф.Хоффманн-Ля Рош Аг |
Бензаннелированные соединения в качестве активаторов ppar
|
WO2005049573A1
(en)
|
2003-11-05 |
2005-06-02 |
F. Hoffmann-La Roche Ag |
Phenyl derivatives as ppar agonists
|
WO2005056522A2
(en)
|
2003-12-04 |
2005-06-23 |
National Health Research Institutes |
Indole compounds
|
TWI297606B
(en)
*
|
2004-01-16 |
2008-06-11 |
Nat Health Research Institutes |
Cancer therapy
|
JP2007534702A
(ja)
*
|
2004-04-26 |
2007-11-29 |
バンダービルト・ユニバーシティ |
胃腸毒性の低い治療薬としてのインドール酢酸、及びインデン酢酸誘導体
|
US20080076810A1
(en)
*
|
2004-05-28 |
2008-03-27 |
Weiguo Lui |
Benzoureas Having Anti-Diabetic Activity
|
EP2336113A1
(de)
*
|
2004-05-29 |
2011-06-22 |
7TM Pharma A/S |
CRTH2-Rezeptorliganden zur medizinischen Anwendung
|
MXPA06014084A
(es)
*
|
2004-06-04 |
2007-02-15 |
Merck & Co Inc |
Derivados de pirazol, composiciones que contienen dichos compuestos y metodos de uso.
|
WO2006014262A2
(en)
|
2004-07-02 |
2006-02-09 |
Merck & Co., Inc. |
Indoles having anti-diabetic activity
|
ATE468853T1
(de)
|
2004-07-22 |
2010-06-15 |
Merck Sharp & Dohme |
Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
|
ES2313401T3
(es)
|
2004-07-30 |
2009-03-01 |
Laboratorios Salvat, S.A. |
Derivados de tirosina como moduladores de ppar-gamma.
|
EP1799242A4
(de)
*
|
2004-09-16 |
2009-11-11 |
Univ California |
Peptide vom typ g und andere wirkstoffe zur linderung von atherosklerose und anderen erkrankungen
|
JP2008019169A
(ja)
*
|
2004-10-25 |
2008-01-31 |
Osaka Univ |
新規ppar調節剤およびそのスクリーニング方法
|
US20060122222A1
(en)
*
|
2004-11-18 |
2006-06-08 |
The Institutes For Pharmaceutical Discovery, Llc |
Heterocycle substituted carboxylic acids
|
CN101115496B
(zh)
|
2004-12-06 |
2012-03-07 |
加州大学评议会 |
改善微动脉的结构和功能的方法
|
DOP2006000008A
(es)
*
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
FR2880887B1
(fr)
*
|
2005-01-14 |
2009-01-30 |
Merck Sante Soc Par Actions Si |
Derives d'hydroxyphenols, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
|
RU2007136784A
(ru)
|
2005-03-04 |
2009-04-10 |
Мерк энд Ко., Инк. (US) |
Конденсированные ароматические соединения, обладающие антидиабетической активностью
|
US20080293639A1
(en)
*
|
2005-04-29 |
2008-11-27 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
NZ563187A
(en)
*
|
2005-04-29 |
2010-05-28 |
Univ California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
CN101184484B
(zh)
*
|
2005-05-24 |
2011-10-05 |
帝斯曼知识产权资产管理有限公司 |
用于治疗炎性失调的藁本内酯衍生物
|
CA2612765A1
(en)
|
2005-07-06 |
2007-01-18 |
Merck And Co., Inc. |
Antidiabetic oxazolidinediones and thiazolidinediones
|
AU2006276072A1
(en)
|
2005-07-26 |
2007-02-08 |
Merck Sharp & Dohme Corp. |
Process for synthesizing a substituted pyrazole
|
US20070161006A1
(en)
*
|
2006-01-10 |
2007-07-12 |
Vita Genomics, Inc. |
Single nucleotide polymorphisms in protein-tyrosine phosphatase receptor-type delta for the diagnosis of susceptibility to infection and asthma
|
PE20071221A1
(es)
*
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
JP4521838B2
(ja)
*
|
2006-04-11 |
2010-08-11 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
個体において骨質量を増加させるために有用である化合物を同定するためにgpr119受容体を用いる方法
|
US7736624B2
(en)
|
2006-06-19 |
2010-06-15 |
Univ Vanderbilt |
Methods and compositions for diagnostic and therapeutic targeting of COX-2
|
AU2007292883B2
(en)
|
2006-09-08 |
2013-09-05 |
Rhode Island Hospital |
Treatment, prevention, and reversal of alcohol-induced brain disease
|
US8168815B2
(en)
|
2007-01-26 |
2012-05-01 |
Kaneq Pharma Inc. |
Fused aromatic PTP-1B inhibitors
|
JP5301469B2
(ja)
|
2007-02-26 |
2013-09-25 |
メルク カナダ インコーポレイテッド |
Ep4受容体アンタゴニストとしてのインドール及びインドリンシクロプロピルアミド誘導体
|
US8338458B2
(en)
|
2007-05-07 |
2012-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fused aromatic compounds having anti-diabetic activity
|
US20080319218A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Andreas Haubrich |
Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
|
US20080319221A1
(en)
*
|
2007-06-22 |
2008-12-25 |
Bernd Junker |
Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
|
AU2008296487A1
(en)
|
2007-08-28 |
2009-03-12 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
AU2008296478B9
(en)
|
2007-08-28 |
2015-03-19 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
FR2921366B1
(fr)
*
|
2007-09-26 |
2009-12-04 |
Servier Lab |
Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
DE102007063671A1
(de)
*
|
2007-11-13 |
2009-06-25 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
EP2146210A1
(de)
|
2008-04-07 |
2010-01-20 |
Arena Pharmaceuticals, Inc. |
Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
|
JO2870B1
(en)
|
2008-11-13 |
2015-03-15 |
ميرك شارب اند دوهم كورب |
Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes
|
EP2358200A4
(de)
|
2008-11-17 |
2012-05-16 |
Merck Sharp & Dohme |
Substituierte bizyklische amine für die behandlung von diabetes
|
TW201028414A
(en)
|
2009-01-16 |
2010-08-01 |
Merck Sharp & Dohme |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
EP2389226B1
(de)
|
2009-01-23 |
2013-11-20 |
Merck Sharp & Dohme Corp. |
Gebrückte und fusionierte heterozyklische antidiabeteszusammensetzungen
|
CA2749891A1
(en)
|
2009-01-23 |
2010-07-29 |
Hubert B. Josien |
Bridged and fused antidiabetic compounds
|
US8575166B2
(en)
|
2009-02-05 |
2013-11-05 |
Merck Sharp & Dohme Corp. |
Phthalazine-containing antidiabetic compounds
|
US20120220567A1
(en)
|
2009-07-23 |
2012-08-30 |
Shipps Jr Gerald W |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
EP2464228B1
(de)
|
2009-08-13 |
2017-12-06 |
Merck Sharp & Dohme Corp. |
Substituierte cyclopropylverbindungen, zusammensetzungen mit solchen verbindungen und behandlungsverfahren damit
|
CN102595897A
(zh)
|
2009-09-02 |
2012-07-18 |
默沙东公司 |
作为用于糖尿病的治疗或预防的二肽基肽酶-iv抑制剂的氨基四氢吡喃
|
WO2011088025A1
(en)
|
2010-01-15 |
2011-07-21 |
Merck Sharp & Dohme Corp. |
Oxadiazole beta carboline derivatives as antidiabetic compounds
|
EP2538783B1
(de)
|
2010-02-22 |
2016-06-01 |
Merck Sharp & Dohme Corp. |
Substituierte aminotetrahydrothiopyrane als dipeptidylpeptidase-iv-hemmer zur behandlung von diabetes
|
US8785634B2
(en)
|
2010-04-26 |
2014-07-22 |
Merck Sharp & Dohme Corp |
Spiropiperidine prolylcarboxypeptidase inhibitors
|
US9365539B2
(en)
|
2010-05-11 |
2016-06-14 |
Merck Sharp & Dohme Corp. |
Prolylcarboxypeptidase inhibitors
|
US8980929B2
(en)
|
2010-05-21 |
2015-03-17 |
Merck Sharp & Dohme Corp. |
Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
|
WO2011156246A1
(en)
|
2010-06-11 |
2011-12-15 |
Merck Sharp & Dohme Corp. |
Novel prolylcarboxypeptidase inhibitors
|
WO2012024183A1
(en)
|
2010-08-18 |
2012-02-23 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
BR112013008100A2
(pt)
|
2010-09-22 |
2016-08-09 |
Arena Pharm Inc |
"moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
|
AU2011320595A1
(en)
|
2010-10-29 |
2013-06-06 |
Merck Sharp & Dohme Corp. |
Diazeniumdiolate heterocyclic derivatives
|
MX351305B
(es)
|
2011-01-20 |
2017-10-09 |
Merck Sharp & Dohme |
Antagonistas del receptor de mineralocorticoides.
|
JO3350B1
(ar)
|
2011-03-07 |
2019-03-13 |
Merck Sharp & Dohme |
مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
|
EP2693882B1
(de)
|
2011-04-08 |
2017-06-28 |
Merck Sharp & Dohme Corp. |
Substituierte cyclopropylverbindungen, zusammensetzungen mit solchen verbindungen und behandlungsverfahren damit
|
US9487506B2
(en)
|
2011-04-13 |
2016-11-08 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
EP2704568B1
(de)
|
2011-05-02 |
2018-01-24 |
Merck Sharp & Dohme Corp. |
Diazeniumdiolat-cyclohexyl-derivate
|
US20140088124A1
(en)
|
2011-06-02 |
2014-03-27 |
Robert J. DeVita |
Imidazole derivatives
|
CA2838079A1
(en)
|
2011-06-16 |
2012-12-20 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
WO2012178142A1
(en)
*
|
2011-06-23 |
2012-12-27 |
Metabolic Solutions Development Company, Llc |
Ppar-sparing compounds and combinations fort the treatment of diabetes and other metabolic diseases
|
EP2760855B1
(de)
|
2011-09-30 |
2017-03-15 |
Merck Sharp & Dohme Corp. |
Substituierte cyclopropylverbindungen, zusammensetzungen mit solchen verbindungen und ihre verwendung bei der behandlung von typ-2 diabetes
|
WO2013055606A1
(en)
|
2011-10-13 |
2013-04-18 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
US9346803B2
(en)
|
2011-10-17 |
2016-05-24 |
Vanderbilt University |
Indomethacin analogs for the treatment of castrate-resistant prostate cancer
|
US9018200B2
(en)
|
2011-10-24 |
2015-04-28 |
Merck Sharp & Dohme Corp. |
Substituted piperidinyl compounds useful as GPR119 agonists
|
JO3210B1
(ar)
|
2011-10-28 |
2018-03-08 |
Merck Sharp & Dohme |
مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
|
WO2013068328A1
(en)
|
2011-11-07 |
2013-05-16 |
Intervet International B.V. |
Bicyclo [2.2.2] octan-1-ylcarboxylic acid compounds as dgat-1 inhibitors
|
WO2013068439A1
(en)
|
2011-11-09 |
2013-05-16 |
Intervet International B.V. |
4-amino-5-oxo-7,8-dihydropyrimido[5, 4 -f] [1, 4] oxazepine compounds as dgat1 inhibitors
|
CA2855009C
(en)
|
2011-11-15 |
2019-07-09 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as gpr119 agonists
|
EP2814485A4
(de)
|
2012-02-17 |
2015-08-26 |
Merck Sharp & Dohme |
Dipeptidylpeptidase-iv-inhibitoren zur behandlung oder prävention von diabetes
|
CN104411710A
(zh)
|
2012-04-16 |
2015-03-11 |
卡内克制药公司 |
作为ptp-1b抑制剂前体的稠合的芳族膦酸酯衍生物
|
US9315508B2
(en)
|
2012-07-23 |
2016-04-19 |
Merck Sharp & Dohme Corp. |
Treating diabetes with dipeptidyl peptidase-IV inhibitors
|
US9453038B2
(en)
|
2012-12-17 |
2016-09-27 |
Merck Sharp & Dohme Corp. |
Glucokinase activator compounds, compositions containing such compounds, and methods of treatment
|
US9717714B2
(en)
|
2012-12-19 |
2017-08-01 |
Merck Sharp & Dohme Corp. |
Spirocyclic CETP inhibitors
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
US10065945B2
(en)
|
2014-01-24 |
2018-09-04 |
Merck Sharp & Dohme Corp. |
Isoquinoline derivatives as MGAT2 inhibitors
|
WO2016018729A1
(en)
|
2014-07-29 |
2016-02-04 |
Merck Sharp & Dohme Corp. |
Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein
|
EP3189069A4
(de)
|
2014-07-31 |
2018-03-07 |
UAB Research Foundation |
Apoe-mimetische peptide und erhöhte wirksamkeit für klares plasmacholesterol
|
WO2016022446A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[5,6]-fused bicyclic antidiabetic compounds
|
WO2016022448A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
EP3177287B1
(de)
|
2014-08-08 |
2022-02-23 |
Merck Sharp & Dohme Corp. |
Antidiabetische bicyclische verbindungen
|
JP6581656B2
(ja)
|
2014-10-24 |
2019-09-25 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
グルカゴンおよびglp−1受容体のコアゴニスト
|
TW201625635A
(zh)
|
2014-11-21 |
2016-07-16 |
默沙東藥廠 |
作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
|
US11007175B2
(en)
|
2015-01-06 |
2021-05-18 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the S1P1 receptor
|
EP3303342B1
(de)
|
2015-05-27 |
2021-03-17 |
Merck Sharp & Dohme Corp. |
Als lösliche guanylat-cyclase-aktivatoren geeignete imidazopyrazinylderivate
|
EP3310782B1
(de)
|
2015-05-28 |
2021-12-01 |
Merck Sharp & Dohme Corp. |
Als lösliche guanylat-cyclase-aktivatoren geeignete imidazopyrazinylderivate
|
NZ738862A
(en)
|
2015-06-22 |
2023-12-22 |
Arena Pharm Inc |
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
|
WO2017011279A1
(en)
|
2015-07-13 |
2017-01-19 |
Merck Sharp & Dohme Corp. |
Bicyclic heterocycles as inhibitors of cholesterol ester transfer protein
|
US10800826B2
(en)
|
2015-10-05 |
2020-10-13 |
Merck Sharp & Dohme Corp. |
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
|
EP3383868B1
(de)
|
2015-11-30 |
2022-10-05 |
Merck Sharp & Dohme LLC |
Arylsulfonamide als blt1-antagonisten
|
WO2017095725A1
(en)
|
2015-11-30 |
2017-06-08 |
Merck Sharp & Dohme Corp. |
Aryl sulfonamides as blt1 antagonists
|
WO2017107052A1
(en)
|
2015-12-22 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase stimulators
|
WO2017197555A1
(en)
|
2016-05-16 |
2017-11-23 |
Merck Sharp & Dohme Corp. |
Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
|
WO2017201683A1
(en)
|
2016-05-25 |
2017-11-30 |
Merck Sharp & Dohme Corp. |
Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists
|
EP3496716B1
(de)
|
2016-08-15 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Verbindungen zur änderung der konzentrationen von gallensäuren zur behandlung von diabetes und kardiometabolischen erkrankungen
|
WO2018034917A1
(en)
|
2016-08-15 |
2018-02-22 |
Merck Sharp & Dohme Corp. |
Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
|
WO2018057409A1
(en)
|
2016-09-20 |
2018-03-29 |
Merck Sharp & Dohme Corp. |
Substituted 1-methyl-1,2,3,4-tetrahydroisoquinoline molecules as pcsk9 allosteric binders
|
CN109963561A
(zh)
|
2016-11-18 |
2019-07-02 |
默沙东公司 |
可用作二酰基甘油酯o-酰基转移酶2的抑制剂的吲哚衍生物
|
WO2018107415A1
(en)
|
2016-12-15 |
2018-06-21 |
Merck Sharp & Dohme Corp. |
Hydroxy isoxazole compounds useful as gpr120 agonists
|
CA3053418A1
(en)
|
2017-02-16 |
2018-08-23 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of primary biliary cholangitis
|
JOP20190150A1
(ar)
|
2018-06-21 |
2019-12-21 |
Merck Sharp & Dohme |
مركبات مناهضة لـ pcsk9
|
US20220177465A1
(en)
|
2019-04-04 |
2022-06-09 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
WO2020236688A1
(en)
|
2019-05-22 |
2020-11-26 |
Merck Sharp & Dohme Corp. |
Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
|
EP3972589A4
(de)
|
2019-05-22 |
2023-04-26 |
Merck Sharp & Dohme LLC |
Natriuretische peptid-rezeptor-a-agonisten zur behandlung von kardiometabolischen erkrankungen, nierenerkrankungen und diabetes
|
EP4021919A1
(de)
|
2019-08-30 |
2022-07-06 |
Merck Sharp & Dohme Corp. |
Pcsk9-antagonist-verbindungen
|
EP3842061A1
(de)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Geheftete triazol-co-agonisten der glucagon- und glp-1-rezeptoren
|
EP3842060A1
(de)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Geheftete lactam-co-agonisten der glucagon- und glp-1-rezeptoren
|
EP3842449A1
(de)
|
2019-12-23 |
2021-06-30 |
Merck Sharp & Dohme Corp. |
Geklammerte olefin-co-agonisten der glucagon- und glp-1-rezeptoren
|
WO2021236401A1
(en)
|
2020-05-18 |
2021-11-25 |
Merck Sharp & Dohme Corp. |
Novel diacylglyceride o-acyltransferase 2 inhibitors
|
CA3228604A1
(en)
|
2021-08-19 |
2023-02-23 |
Merck Sharp & Dohme Llc |
Compounds for treating conditions related to pcsk9 activity
|
WO2023244554A1
(en)
|
2022-06-15 |
2023-12-21 |
Merck Sharp & Dohme Llc |
Cyclic peptides for trapping interleukin-1 beta
|